Vistagen Therapeutics's earnings per share without non-recurring items for the
three
months ended in Dec. 2023 was $-0.22.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 17.20% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Vistagen Therapeutics's EPS without NRI or its related term are showing as below:
VTGN'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0.6 Med: 31.3 Max: 64.1
Current: 17.2
During the past 13 years, Vistagen Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 64.10% per year. The lowest was 0.60% per year. And the median was 31.30% per year.
VTGN's 3-Year EPS without NRI Growth Rate is ranked better than 64.86% of 1295
companies
in the Biotechnology industry
Industry Median: 4.7
vs VTGN: 17.20
Vistagen Therapeutics's EPS (Diluted) for the
three
months ended in Dec. 2023 was $-0.22.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.
Vistagen Therapeutics's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.22.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.51.
Vistagen Therapeutics EPS without NRI Historical Data
The historical data trend for Vistagen Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vistagen Therapeutics's EPS without NRI
For the Biotechnology subindustry, Vistagen Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's PE Ratio without NRI falls into.
Vistagen Therapeutics EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (NAS:VTGN) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Vistagen Therapeutics EPS without NRI Related Terms
Thank you for viewing the detailed overview of Vistagen Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your 